OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection.